Holen Sie sich die Stockscreener-App
1.59
0.63%
-0.01
Veraxa Biotech Ag Aktie (VRXA) Neueste Nachrichten
VERAXA Biotech Designates Raju Willener as CFO - finance.yahoo.com
Veraxa Biotech (VRXA) Insider Trading Activity 2026 - MarketBeat
Veraxa Biotech AG (NASDAQ: VRXA) Names Raju Willener as CFO Following De-SPAC Completion - Kalkine Media
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officer - TradingView
VRXA Rises As Veraxa Biotech AG Draws Trader Focus - timothysykes.com
Veraxa Biotech AG Company Profile & Introduction - Moomoo
VRXA Jumps As Traders Focus On Biotech Breakout Setup - timothysykes.com
VRXA Should I Buy - Intellectia AI
VERAXA Biotech Appoints Veteran Finance Executive Raju Willener as CFO to Drive Capital Strategy and Oncology Pipeline Growth - citybuzz -
Veraxa Biotech AG (VRXA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Veraxa Biotech AG Announces Chief Financial Officer Changes - marketscreener.com
Veraxa Biotech stock rises after naming Raju Willener as CFO - Investing.com India
Veraxa Biotech stock rises after naming Raju Willener as CFO By Investing.com - Investing.com South Africa
Veraxa Biotech names Raju Willener as chief financial officer By Investing.com - Investing.com South Africa
Finance veteran behind CHF 30B portfolios joins Veraxa Biotech (VRXA) as CFO - Stock Titan
Veraxa Biotech names Raju Willener as chief financial officer - Investing.com
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer - 富途牛牛
Veraxa Biotech (VRXA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Insider Buys Additional CHF75k In Veraxa Biotech Stock - simplywall.st
Veraxa Biotech (VRXA) Stock Price, News & Analysis - MarketBeat
Veraxa Biotech (VRXA) Stock Chart and Price History 2026 - MarketBeat
Veraxa Biotech (VRXA) director adds 50K shares in open-market buy - Stock Titan
Veraxa Biotech (VRXA) CEO now holds 5,000 ordinary shares - Stock Titan
VERAXA Biotech (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation T - Benzinga
Early lab data advance Veraxa (Nasdaq: VRXA) autoimmune AOC - stocktitan.net
Veraxa and Secarna report positive early results from AOC study By Investing.com - Investing.com India
Veraxa Biotech AG - Via Ritzau
VERAXA Biotech Advances VXA-222 Cancer Program Beyond Discovery Phase, Strengthens IP Portfolio - citybuzz -
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan
Veraxa Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -
Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies - finance.yahoo.com
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan
VERAXA Biotech (VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform - Yahoo Finance
VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms - USA Today
Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada
Veraxa Biotech files first BiTAC patent applications in 2026 - Investing.com
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):